These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1308 related items for PubMed ID: 28385467

  • 1. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo® wireless esophageal pH monitoring study.
    Schey R, Alla SP, Midani D, Parkman HP.
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [Abstract] [Full Text] [Related]

  • 2. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.
    Yadlapati R, Masihi M, Gyawali CP, Carlson DA, Kahrilas PJ, Nix BD, Jain A, Triggs JR, Vaezi MF, Kia L, Kaizer A, Pandolfino JE.
    Gastroenterology; 2021 Jan; 160(1):174-182.e1. PubMed ID: 32949568
    [Abstract] [Full Text] [Related]

  • 3. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S.
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [Abstract] [Full Text] [Related]

  • 4. [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].
    Huamán JW, Aliaga V, Domenech G, Videla S, Saperas E.
    Gastroenterol Hepatol; 2014 Oct; 37(8):452-61. PubMed ID: 24725608
    [Abstract] [Full Text] [Related]

  • 5. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G, Vassalle J, Marcus SN, Triadafilopoulos G.
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV, Viazis N, Vlachogiannakos J, Sgouros SN, Stefanidis G, Archimandritis A, Karamanolis DG.
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [Abstract] [Full Text] [Related]

  • 7. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
    Liang XY, Chen WN, Lan L, Wang Q, Lü YW, Lan Y.
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
    [Abstract] [Full Text] [Related]

  • 8. [The Additional Role of Symptom-Reflux Association Analysis of Diagnosis of Gastroesophageal Reflux Disease Using Bravo Capsule pH Test].
    Jung K, Park MI, Park SJ, Moon W, Kim SE, Kim JH.
    Korean J Gastroenterol; 2017 Oct 25; 70(4):169-175. PubMed ID: 29060954
    [Abstract] [Full Text] [Related]

  • 9. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N, Nacci A, Savarino E, Martinucci I, Bellini M, Fattori B, Ceccarelli L, Costa F, Mumolo MG, Ricchiuti A, Savarino V, Berrettini S, Marchi S.
    World J Gastroenterol; 2012 Aug 28; 18(32):4363-70. PubMed ID: 22969200
    [Abstract] [Full Text] [Related]

  • 10. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
    Becker V, Grotz S, Schlag C, Nennstiel S, Beitz A, Haller B, Schmid RM, Meining A, Bajbouj M.
    World J Gastroenterol; 2014 Apr 14; 20(14):4017-24. PubMed ID: 24744591
    [Abstract] [Full Text] [Related]

  • 11. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P, Jones R, Vakil N, Junghard O, Lind T, Wernersson B, Dent J.
    Clin Gastroenterol Hepatol; 2012 Dec 14; 10(12):1360-6. PubMed ID: 22813439
    [Abstract] [Full Text] [Related]

  • 12. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ.
    Am J Gastroenterol; 2008 Oct 14; 103(10):2446-53. PubMed ID: 18684197
    [Abstract] [Full Text] [Related]

  • 13. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
    Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO.
    Dis Esophagus; 2012 Oct 14; 25(8):682-6. PubMed ID: 22292567
    [Abstract] [Full Text] [Related]

  • 14. Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery.
    Ward MA, Dunst CM, Teitelbaum EN, Halpin VJ, Reavis KM, Swanström LL, DeMeester SR.
    Surg Endosc; 2018 Feb 14; 32(2):889-894. PubMed ID: 28779252
    [Abstract] [Full Text] [Related]

  • 15. 24 Versus 48-hour bravo pH monitoring.
    Chander B, Hanley-Williams N, Deng Y, Sheth A.
    J Clin Gastroenterol; 2012 Mar 14; 46(3):197-200. PubMed ID: 21959323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease.
    Januszewicz W, Hartley J, Waldock W, Roberts G, Alias B, Hobson A, Wernisch L, di Pietro M.
    United European Gastroenterol J; 2019 Dec 01; 7(10):1389-1398. PubMed ID: 31807307
    [Abstract] [Full Text] [Related]

  • 18. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
    Abdallah J, George N, Yamasaki T, Ganocy S, Fass R.
    Clin Gastroenterol Hepatol; 2019 May 01; 17(6):1073-1080.e1. PubMed ID: 29913281
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.
    Yadlapati R, Gyawali CP, Pandolfino JE, CGIT GERD Consensus Conference Participants.
    Clin Gastroenterol Hepatol; 2022 May 01; 20(5):984-994.e1. PubMed ID: 35123084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.